随机试验中实时计算机辅助检测结直肠肿瘤的功效
这项在意大利3个中心开展的多中心随机试验纳入685名受试者,比较实时计算机辅助检测(CADe)系统与标准高清结肠镜在筛查性结肠镜检查中的效果。结果显示CADe组腺瘤检出率(54.8%)显著高于对照组(40.4%),每例结肠镜检出腺瘤数亦显著增加,且不延长退镜时间。
要点
- CADe组腺瘤检出率54.8%,显著高于对照组40.4%(RR 1.30;95%CI 1.14-1.45)。
- CADe组每例结肠镜检出腺瘤数均值1.07±1.54,显著高于对照组0.71±1.20(发生率比1.46;95%CI 1.15-1.86)。
- 两组退镜时间无显著差异(CADe组417±101秒 vs 对照组435±149秒;P=0.1)。
核心结论
- 在多中心随机试验中,将CADe纳入实时结肠镜检查可显著提高腺瘤检出率和每例结肠镜检出腺瘤数,且不增加退镜时间。
研究设计与样本
- 多中心、随机试验,于2019年9月至11月在意大利3个中心开展。
- 共分析685名受试者(年龄61.32±10.2岁;男性337名),因结直肠癌筛查、息肉切除后监测或粪便免疫化学检测阳性/结直肠癌症状体征而行结肠镜检查。
- 受试者按1:1随机分配至CADe系统辅助的高清结肠镜组或对照组(不采用CADe)。
- CADe系统为基于人工智能的医疗设备(GI-Genius,Medtronic),实时在內镜显示屏上以绿框叠加标记疑似病变。
- 要求退镜时间至少6分钟,病变经组织病理学检查作为参考标准。
主要发现
- CADe组腺瘤检出率为54.8%,显著高于对照组40.4%(RR 1.30;95%CI 1.14-1.45)。
- CADe组每例结肠镜检出腺瘤数均值为1.07±1.54,显著高于对照组0.71±1.20(发生率比1.46;95%CI 1.15-1.86)。
- ≤5 mm腺瘤在CADe组受试者中检出比例33.7%,显著高于对照组26.5%(RR 1.26;95%CI 1.01-1.52)。
- 6-9 mm腺瘤在CADe组受试者中检出比例10.6%,显著高于对照组5.8%(RR 1.78;95%CI 1.09-2.86),无论形态或位置。
- 两组退镜时间无显著差异(CADe组417±101秒 vs 对照组435±149秒;P=0.1),非肿瘤性病变切除比例亦无显著差异(CADe组26.0% vs 对照组28.7%;RR 1.00;95%CI 0.90-1.12)。
关键数值与推荐
- 主要结局为腺瘤检出率(ADR,至少1个组织学证实的腺瘤或癌的受试者百分比)。
- 次要结局包括每例结肠镜检出腺瘤数、非肿瘤性病变切除率和退镜时间。
临床怎么用
- 原文未据本研究结果给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: One-fourth of colorectal neoplasias are missed during screening colonoscopies; these can develop into colorectal cancer (CRC). Deep learning systems allow for real-time computer-aided detection (CADe) of polyps with high accuracy. We performed a multicenter, randomized trial to assess the safety and efficacy of a CADe system in detection of colorectal neoplasias during real-time colonoscopy. METHODS: We analyzed data from 685 subjects (61.32 ± 10.2 years old; 337 men) undergoing screening colonoscopies for CRC, post-polypectomy surveillance, or workup due to positive results from a fecal immunochemical test or signs or symptoms of CRC, at 3 centers in Italy from September through November 2019. Patients were randomly assigned (1:1) to groups who underwent high-definition colonoscopies with the CADe system or without (controls). The CADe system included an artificial intelligence-based medical device (GI-Genius, Medtronic) trained to process colonoscopy images and superimpose them, in real time, on the endoscopy display a green box over suspected lesions. A minimum withdrawal time of 6 minutes was required. Lesions were collected and histopathology findings were used as the reference standard. The primary outcome was adenoma detection rate (ADR, the percentage of patients with at least 1 histologically proven adenoma or carcinoma). Secondary outcomes were adenomas detected per colonoscopy, non-neoplastic resection rate, and withdrawal time. RESULTS: The ADR was significantly higher in the CADe group (54.8%) than in the control group (40.4%) (relative risk [RR], 1.30; 95% confidence interval [CI], 1.14-1.45). Adenomas detected per colonoscopy were significantly higher in the CADe group (mean, 1.07 ±1.54) than in the control group (mean 0.71 ± 1.20) (incidence rate ratio, 1.46; 95% CI, 1.15-1.86). Adenomas 5 mm or smaller were detected in a significantly higher proportion of subjects in the CADe group (33.7%) than in the control group (26.5%; RR, 1.26; 95% CI, 1.01-1.52), as were adenomas of 6 to 9 mm (detected in 10.6% of subjects in the CADe group vs 5.8% in the control group; RR, 1.78; 95% CI, 1.09-2.86), regardless of morphology or location. There was no significant difference between groups in withdrawal time (417 ± 101 seconds for the CADe group vs 435 ± 149 for controls; P = .1) or proportion of subjects with resection of non-neoplastic lesions (26.0% in the CADe group vs 28.7% of controls; RR, 1.00; 95% CI, 0.90-1.12). CONCLUSIONS: In a multicenter, randomized trial, we found that including CADe in real-time colonoscopy significantly increases ADR and adenomas detected per colonoscopy without increasing withdrawal time. ClinicalTrials.gov no: 04079478.
引用
- Repici A, Badalamenti M, Maselli R, et al. Efficacy of Real-Time Computer-Aided Detection of Colorectal Neoplasia in a Randomized Trial. Gastroenterology. 2020. PMID: 32371116. doi:10.1053/j.gastro.2020.04.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。